Cohort Multicenter Study on the Role of Medications in Parenteral Nutrition–Related Alteration of Liver Function Tests in Adults
- 8 May 2020
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 45 (3) , 633-642
Abstract
Background Our objective was to assess the risk in non‐critically‐ill adult inpatients on parenteral nutrition (PN) of developing liver function test (LFT) alterations when receiving concomitant possibly hepatotoxic medications or others reported to improve LFTs during PN. Material and Methods A multicenter retrospective analysis of prospectively collected data was performed on patients receiving PN. Two groups were recruited: group LALT included patients with any LFT alterations during PN, and group NOLALT, those who did not present such alterations. Exclusion criteria were previous sepsis, shock, renal failure, hyperglycemia, LFT alteration or biliopancreatic surgical procedures. Medications were classified into two categories: medications reported to improve LFTs during PN (n = 8) and possibly hepatotoxic medications (n = 54), including a subgroup of possibly highly hepatotoxic medications (n = 30). Results The study included 200 patients, 136 (68.0%) in the LALT group, and 64 (32.0%) in the NOLALT group. The groups differed in the number of patients requiring surgical intervention ≤7 days prior to PN (LALT, 94 [69.1%]; NOLALT, 29 [45.3%]; p<0.002) and in those receiving possibly hepatotoxic medications (LALT, 126 [92.6%]; NOLALT, 45 [70.3%]; p<0.001). Variables in the final Cox regression model were possibly hepatotoxic medications, OR 3.310 (1.678‐6.530); surgical intervention prior to PN, OR 1.861 (1.277‐2.711); baseline triglyceridemia, OR 1.005 (1.001‐1.009) and creatinine, OR 1.861 (1.043‐3.323). Conclusions Patients requiring PN who concomitantly received possibly hepatotoxic medications had a three‐fold risk of developing LFT alterations. Medications reported to improve LFTs during PN had no effect. The use of possibly hepatotoxic medications during PN was associated with LFT alterations. This article is protected by copyright. All rights reservedKeywords
This publication has 32 references indexed in Scilit:
- Hepatic safety of antibiotics used in primary careJournal of Antimicrobial Chemotherapy, 2011
- Perioperative liver protectionCurrent Opinion in Critical Care, 2010
- Factores de riesgo de la disfunción hepática asociada a la nutrición parenteralMedicina Clinica, 2009
- Chronic biochemical cholestasis in patients receiving home parenteral nutrition: prevalence and predisposing factorsAlimentary Pharmacology & Therapeutics, 2008
- Drug-Induced Liver Injury: Review ArticleDigestive Diseases and Sciences, 2007
- Acute and clinically relevant drug‐induced liver injury: a population based case‐control studyBritish Journal of Clinical Pharmacology, 2004
- Total Parenteral Nutrition‐Associated Liver DiseaseJournal of Parenteral and Enteral Nutrition, 2002
- Choline Deficiency Causes Reversible Hepatic Abnormalities in Patients Receiving Parenteral Nutrition: Proof of a Human Choline Requirement: A Placebo‐Controlled TrialJournal of Parenteral and Enteral Nutrition, 2001
- Liver Dysfunction and Energy Source: Results of a Randomized Clinical TrialJournal of Parenteral and Enteral Nutrition, 1993
- Liver Function Tests in Patients Receiving Parenteral NutritionJournal of Parenteral and Enteral Nutrition, 1991